Literature DB >> 22503977

Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor.

Lei Tang1,2, Xiang Ling1, Wensheng Liu1, Gokul M Das1, Fengzhi Li1.   

Abstract

Growing evidence suggests a role for the antiapoptotic protein survivin in promotion of cancer cell G1/S transition and proliferation. However, the underlying mechanism is unclear. Further, although upregulation of p21(WAF1/CIP1) by p53 plays an important role in p53-mediated cell G1 arrests in response to various distresses, it is unknown whether survivin plays a role in the regulation of p21(WAF1/CIP1) expression. Here, we report that exogenous expression of survivin in p53-wild type MCF-7 breast cancer cells inhibits the expression of p21(WAF1/CIP1) protein, mRNA and promoter activity, while the survivin C84A mutant and antisense failed to do so. Cotransfection experiments in the p53 mutant H1650 lung cancer cell line showed that survivin neutralizes p53-induced p21(WAF1/CIP1) expression and promoter activity. Importantly, genetically silencing of endogenous survivin using lentiviral survivin shRNA also enhances endogenous p21 in p53 wild type cancer cells, suggesting the physiological relevance of the fining. We further demonstrated that both p53 and survivin interacts on the two p53-binding sites in the p21(WAF1/CIP1) promoter (-2313 to -2212; -1452 to -1310), and survivin physically interacts with p53 in cancer cells. Together, we propose that survivin may act as a transcription factor or cofactor to interact with p53 on the p21(WAF1/CIP1) promoter leading to the inhibition of p21(WAF1/CIP1) expression at least in part by neutralizing p53-mediated transcriptional activation of the p21 gene.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503977      PMCID: PMC4439947          DOI: 10.1016/j.bbrc.2012.03.147

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  Survivin study: what is the next wave?

Authors:  Fengzhi Li
Journal:  J Cell Physiol       Date:  2003-10       Impact factor: 6.384

2.  In vitro transcriptional activation of p21 promoter by p53.

Authors:  T K Kim
Journal:  Biochem Biophys Res Commun       Date:  1997-05-19       Impact factor: 3.575

3.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Authors:  A Suzuki; M Hayashida; T Ito; H Kawano; T Nakano; M Miura; K Akahane; K Shiraki
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

4.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.

Authors:  D S O'Connor; D Grossman; J Plescia; F Li; H Zhang; A Villa; S Tognin; P C Marchisio; D C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

5.  Cancer gene therapy using a survivin mutant adenovirus.

Authors:  M Mesri; N R Wall; J Li; R W Kim; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.

Authors:  Xiang Ling; Ralph J Bernacki; Michael G Brattain; Fengzhi Li
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

7.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

Authors:  T Waldman; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  Survivin regulates the p53 tumor suppressor gene family.

Authors:  Zhanxiang Wang; Seiji Fukuda; Louis M Pelus
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

9.  Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.

Authors:  W S el-Deiry; T Tokino; T Waldman; J D Oliner; V E Velculescu; M Burrell; D E Hill; E Healy; J L Rees; S R Hamilton
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

10.  Pleiotropic cell-division defects and apoptosis induced by interference with survivin function.

Authors:  F Li; E J Ackermann; C F Bennett; A L Rothermel; J Plescia; S Tognin; A Villa; P C Marchisio; D C Altieri
Journal:  Nat Cell Biol       Date:  1999-12       Impact factor: 28.824

View more
  13 in total

1.  Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.

Authors:  Chen Xie; Vinod Vijay Subhash; Arpita Datta; Natalia Liem; Shi Hui Tan; Mei Shi Yeo; Woei Loon Tan; Vivien Koh; Fui Leng Yan; Foong Ying Wong; Wai Keong Wong; Jimmy So; Iain Beehuat Tan; Nisha Padmanabhan; Celestial T Yap; Patrick Tan; Liang Kee Goh; Wei Peng Yong
Journal:  Cell Oncol (Dordr)       Date:  2016-02-11       Impact factor: 6.730

2.  microRNA-mediated survivin control of pluripotency.

Authors:  Kristina Kapinas; Heesun Kim; Matthew Mandeville; Lori A Martin-Buley; Carlo M Croce; Jane B Lian; Andre J van Wijnen; Janet L Stein; Dario C Altieri; Gary S Stein
Journal:  J Cell Physiol       Date:  2015-01       Impact factor: 6.384

Review 3.  Survivin splice variants and their diagnostic significance.

Authors:  Nand K Sah; Chandrabhan Seniya
Journal:  Tumour Biol       Date:  2015-08-06

4.  An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).

Authors:  Xiang Ling; Fengzhi Li
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

5.  A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Authors:  Xiang Ling; Shousong Cao; Qiuying Cheng; James T Keefe; Youcef M Rustum; Fengzhi Li
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

6.  Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.

Authors:  Kyung Song; Eswar Shankar; Jiayi Yang; Kara L Bane; Reema Wahdan-Alaswad; David Danielpour
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

7.  Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

Authors:  Guanzhen Yu; Wenzheng Fang; Tian Xia; Ying Chen; Yunshu Gao; Xiaodong Jiao; Suyun Huang; Jiejun Wang; Zhaosheng Li; Keping Xie
Journal:  Oncotarget       Date:  2015-05-20

8.  Inhibition of the growth of human melanoma cells by methionine enkephalin.

Authors:  Dong-Mei Wang; Guang-Chuan Wang; Jing Yang; Nicolas P Plotnikoff; Noreen Griffin; Yu-Man Han; Rui-Qun Qi; Xing-Hua Gao; Feng-Ping Shan
Journal:  Mol Med Rep       Date:  2016-11-14       Impact factor: 2.952

9.  Survivin contributes to DNA repair by homologous recombination in breast cancer cells.

Authors:  Eloïse Véquaud; Grégoire Desplanques; Pascal Jézéquel; Philippe Juin; Sophie Barillé-Nion
Journal:  Breast Cancer Res Treat       Date:  2015-12-18       Impact factor: 4.872

10.  Survivin co-ordinates formation of follicular T-cells acting in synergy with Bcl-6.

Authors:  Karin M E Andersson; Mikael Brisslert; Nicola Filluelo Cavallini; Mattias N D Svensson; Amanda Welin; Malin C Erlandsson; Michael J Ciesielski; Gergely Katona; Maria I Bokarewa
Journal:  Oncotarget       Date:  2015-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.